Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Wuxi Biologics (Cayman) ( (HK:2269) ).
Wuxi Biologics (Cayman) Inc. announced its Annual General Meeting to be held on June 6, 2025, in Shanghai, China. Key agenda items include the reception of audited financial statements for 2024, re-election and appointment of directors, authorization of directors’ remuneration, and re-appointment of auditors. Additionally, a resolution will be considered to grant directors the mandate to issue and allot shares, not exceeding 10% of the total issued shares, under specified conditions. This meeting is significant for stakeholders as it addresses corporate governance and strategic decisions impacting the company’s future operations.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$30.94 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. operates in the biopharmaceutical industry, providing end-to-end solutions for biologics discovery, development, and manufacturing. The company focuses on offering comprehensive services to global pharmaceutical and biotechnology companies.
Average Trading Volume: 67,577,490
Technical Sentiment Signal: Buy
Current Market Cap: HK$94.03B
For detailed information about 2269 stock, go to TipRanks’ Stock Analysis page.